ASC-618 for Patients With Hemophilia A: Ruhong Jiang, PhD

Video

Ruhong Jiang, PhD, cofounder, president, and chief executive officer of ASC Therapeutics, joins CGTL to discuss the company's AAV8-based gene therapy for patients with hemophilia A, as well as other pipeline activity.

"We are really eager to see how the first dosing of [a] patient [goes] because everything comes from patient data." Ruhong Jiang, PhD, cofounder, president, and chief executive officer of ASC Therapeutics

Fresh off its FDA Fast Track Designation and a positive opinion by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products for its AAV8-based gene therapy for patients with hemophilia A, ASC Therapeutics joined CGTL to discuss the status of ASC-618, as well as other agents in the pipeline.

After receiving Investigational New Drug clearance from the FDA in mid 2021, ASC Therapeutics launched a phase 1/2 trial (NCT04676048) to assess the safety, tolerability, and preliminary efficacy of ASC-618 in patients with hemophilia A.

“These regulatory milestones culminate years of hard work, dedication, and collaborative efforts by our functional teams," Oscar Segurado, MD, PhD, chief medical officer at ASC Therapeutics, said in a statement. "Preclinical studies have shown that ASC618 has the potential to reduce therapeutic dosing and increase durability of hemophilia A gene therapy with a novel bioengineered construct that can improve biosynthesis, protein folding, and secretion of factor VIII.”

In a conversation with CGTL, Ruhong Jiang, PhD, cofounder, president, and chief executive officer of ASC Therapeutics, shares updates from the ongoing study of ASC-618, as well as ASC's progress on ASC-930, a stem cell therapy for the treatment of graft-versus-host disease.

Recent Videos
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.